 |
1 Product |  |
0 Diseases | | 1 Product |
|
1 Trial |  |
1 News |  |
| 12» |
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion: Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension (clinicaltrials.gov) - Mar 18, 2025
P1, N=44, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Recruiting --> Completed
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion: Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects (clinicaltrials.gov) - Mar 17, 2025
P1, N=36, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Recruiting --> Completed Recruiting --> Completed
- || Review, Journal: Andrographolide Sulfonates and Xiyanping: A Review of Chemical Composition, Pharmacological Activities, Clinical Applications, and Adverse Reactions. (Pubmed Central) - Feb 26, 2025
Additionally, the safety of Xiyanping injection remains a topic of some debate. This review systematically examines the chemical composition, pharmacological activities, clinical applications, and adverse reactions of andrographolide sulfonates and their formulation in Xiyanping injection to provide a scientific basis for further research and applications, while also offering valuable insights for the development of similar sulfonated drugs.
- || Clinical, Retrospective data, Journal: Network meta-analysis on 4 types of traditional Chinese medicine injections in the treatment of senile severe pneumonia. (Pubmed Central) - Feb 19, 2025
This review systematically examines the chemical composition, pharmacological activities, clinical applications, and adverse reactions of andrographolide sulfonates and their formulation in Xiyanping injection to provide a scientific basis for further research and applications, while also offering valuable insights for the development of similar sulfonated drugs. Reduning injection, Xiyanping injection, Tanreqing injection, and Xuebijing injection combined with conventional drugs in the treatment of senile severe pneumonia can improve the clinical effect.
- |||||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Enrollment open: Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza (clinicaltrials.gov) - Dec 5, 2024
P3, N=748, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Reduning injection, Xiyanping injection, Tanreqing injection, and Xuebijing injection combined with conventional drugs in the treatment of senile severe pneumonia can improve the clinical effect. Not yet recruiting --> Recruiting
- |||||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Enrollment open: Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications (clinicaltrials.gov) - Dec 4, 2024
P3, N=328, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Enrollment open: Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects (clinicaltrials.gov) - Dec 4, 2024
P1, N=36, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P1 trial: Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects (clinicaltrials.gov) - Nov 7, 2024
P1, N=36, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P1 trial: Study to Assess the Tolerability, Safety and Efficacy of GP681 Powder for Oral Suspension (clinicaltrials.gov) - Oct 16, 2024
P1, N=40, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- |||||||||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P3 trial: Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza (clinicaltrials.gov) - Aug 28, 2024
P3, N=748, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- |||||||||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P3 trial: Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications (clinicaltrials.gov) - Aug 27, 2024
P3, N=328, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- || clindamycin phosphate / Generic mfg.
Retrospective data, Review, Journal: Potential efficacy and safety of Xiyanping injection as adjuvant therapy in treatment of suppurative acute tonsillitis: a meta-analysis, trial sequential analysis, and certainty of evidence. (Pubmed Central) - Jun 27, 2024
When compared to conventional treatments (CTs; ?-lactams/clindamycin hydrochloride injection/ribavirin) alone, the combination of XYP with CTs demonstrated significant reductions in symptom duration...Nonetheless, these findings warrant further confirmation through more rigorous RCTs, given the notable heterogeneity and publication bias observed in the included studies. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=296118, identifier CRD42022296118.
- || Retrospective data, Review, Journal: Efficacy of five different traditional Chinese medicine injections in acute upper respiratory tract infection in children: a network meta-analysis and systematic review. (Pubmed Central) - Jun 25, 2024
The herbal injections combined with ribavirin improved clinical outcomes, and were superior to ribavirin injection alone in alleviating clinical symptoms such as fever, cough, sore throat, runny nose, and nasal congestion, and have favorable safety profiles. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023484099, CRD42023484099.
- | Journal: Efficacy of intramuscular injection of Xiyanping injection for the treatment of acute bronchitis in children: a multicenter, randomized, parallel-controlled clinical study (Pubmed Central) - Nov 26, 2023
https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023484099, CRD42023484099. The overall efficacy of combined routine treatment with intramuscular injection of Xiyanping injection in the treatment of acute bronchitis in children is superior to that of routine treatment alone, without an increase in the incidence of adverse reactions.
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion, Trial completion date, Trial primary completion date: GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers (clinicaltrials.gov) - Nov 15, 2023
P1, N=24, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
The overall efficacy of combined routine treatment with intramuscular injection of Xiyanping injection in the treatment of acute bronchitis in children is superior to that of routine treatment alone, without an increase in the incidence of adverse reactions. Not yet recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Dec 2023 --> Aug 2023
- ||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion, Trial completion date, Trial primary completion date: A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers (clinicaltrials.gov) - Nov 14, 2023
P1, N=54, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Not yet recruiting --> Completed | Trial completion date: Feb 2024 --> Oct 2023 | Trial primary completion date: Dec 2023 --> Aug 2023 Recruiting --> Completed | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Sep 2023
- ||||||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion: To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection (clinicaltrials.gov) - Nov 14, 2023
P3, N=591, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Recruiting --> Completed | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jun 2023 --> Sep 2023 Recruiting --> Completed
- | Preclinical, Journal, IO biomarker: Integrated network pharmacology analysis and in vitro validation revealed the underlying mechanism of Xiyanping injection in treating coronavirus disease 2019. (Pubmed Central) - Sep 1, 2023
Through effective network pharmacology analysis and molecular docking, this study suggests that XYP contains many effective compounds that may target COVID-19 related signaling pathways. Moreover, the in vitro experiment confirmed that XYP could inhibit the cytokine storm by regulating genes or proteins related to immune and inflammatory responses.
- || Xiyanping / Jiangxi Qingfeng Pharma
Retrospective data, Review, Journal, HEOR: Comparative effectiveness of Chinese herbal injections treating for rotavirus enteritis in children: A systematic review and Bayesian network meta-analysis. (Pubmed Central) - May 1, 2023
The results showed that YHN [OR=6.16, 95% CI (4.39, 8.77)] had a superior effect in improving clinical effective rate compared to Ribavirin based on Western medicine (WM)...From the comprehensive evaluations of both the clinical effective rate and other outcomes, YHN also indicated a favorable therapeutic effect in RVE. PROSPERO, CRD42022357149.
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P1 trial: GP681 in Volunteers With Hepatic Impairment Compared With Healthy Volunteers (clinicaltrials.gov) - Apr 18, 2023
P1, N=24, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P1 trial: A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers (clinicaltrials.gov) - Mar 29, 2023
P1, N=54, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||| Xiyanping / Jiangxi Qingfeng Pharma
Journal, Adverse events: Variable importance for projection (VIP) scores for analyzing the contribution of risk factors in severe adverse events to Xiyanping injection. (Pubmed Central) - Feb 15, 2023
It is recommended that clinicians pay closer attention to the metabolic characteristics of different age groups. It is safe to use XYP alone and strictly implementing standardized operations such as medication interval and flushing will avoid undesired AEs.
- | Xiyanping / Jiangxi Qingfeng Pharma
Retrospective data, Journal: The efficacy of traditional Chinese medicine in the treatment of the COVID-19 pandemic in Henan Province: a retrospective study. (Pubmed Central) - Feb 15, 2023
It is safe to use XYP alone and strictly implementing standardized operations such as medication interval and flushing will avoid undesired AEs. TCM combined with CWM improved clinical symptoms and reduced hospitalization and mortality rates.
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharm, BR790 / Jiangxi Qingfeng Pharma
New P1/2 trial, Combination therapy, Metastases: BR790 in Combination With Anlotinib in Adult Subjects With Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 8, 2023
P1/2, N=90, Not yet recruiting, Sponsor: Shanghai Gopherwood Biotech Co., Ltd.
- | Xiyanping / Jiangxi Qingfeng Pharma
Retrospective data, Journal: Network Meta-analysis of different Chinese medicine injections combined with conventional therapy in treatment of stroke-associated pneumonia (Pubmed Central) - Dec 7, 2022
The clinical efficacy of Tanreqing Injection, Xuebijing Injection, Xiyanping Injection, Xingnaojing Injection, Shenmai Injection, or Shenfu Injection combined with conventional therapy was superior to that of conventional therapy alone. However, due to the limitations of the quality and methodology of different intervention measures, this conclusion needs to be verified by more high-quality and rigorously designed randomized controlled trial.
- | Xiyanping / Jiangxi Qingfeng Pharma
Preclinical, Journal: Mitochondrial toxicity evaluation of traditional Chinese medicine injections with a dual in vitro approach. (Pubmed Central) - Nov 22, 2022
Furthermore, we identified scutellarin, rutin, phillyrin, and baicalin could be the potential mitochondrial toxic ingredients in the 4 TCM injections by combining molecular docking analysis with experimental validation. Collectively, the dual in vitro approach is worth applying to the safety evaluation of more TCM products, and mitochondrial toxic TCM injections and ingredients found in this study deserve more attention.
- || Xiyanping / Jiangxi Qingfeng Pharma
Retrospective data, Review, Journal: Comparative efficacy and safety of antiviral traditional Chinese medicine injections for viral pneumonia: a systematic review and network meta-analysis. (Pubmed Central) - Nov 2, 2022
According to NMA, Reduning Injection combined with conventional antiviral drugs (CAD) produced superior effects in the effective outcomes and reduced the adverse event incidence rate of VP. This study indicated that TCMIs combined with CAD was more effective and safer than CAD monotherapy and compared different TCMIs therapies, which provided guidance and reference for the selection of clinical treatment medication.
- | Xiyanping / Jiangxi Qingfeng Pharma
Journal: Efficacy of Xiyanping in the Treatment of Elderly Patients with Chronic Obstructive Pulmonary Disease and Its Effect on the Expression of GDF-15 and HIF-1α in Serum. (Pubmed Central) - Oct 25, 2022
The duration of antibiotic use and length of stay in the observation group were significantly shorter than those of the control group, while the incidence of adverse reactions was not statistically significantly different compared with the control group (P > 0.05). Xiyanping can improve pulmonary function of elderly patients with acute exacerbation of COPD, reduce the response of airway hyperreactivity, and promote the excretion of sputum.
- || Xiyanping / Jiangxi Qingfeng Pharma
Retrospective data, Review: Xiyanping injection combined with acitretin for psoriasis vulgaris: A systematic review and meta-analysis. (Pubmed Central) - Sep 24, 2022
As suggested in the present meta-analysis, XYP combined with acitretin effectively and safely treats PV. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022333273, identifier PROSPERO 2022 CRD42022333273.
- | Tevimbra (tislelizumab-jsgr) / BeiGene, BR790 / Jiangxi Qingfeng Pharma
New P1/2 trial, Combination therapy, Metastases: Phase I/IIa Study of BR790 in Combination With Tislelizumab in Adult Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Aug 18, 2022
P1/2, N=160, Recruiting, Sponsor: Shanghai Gopherwood Biotech Co., Ltd.
- | Xiyanping / Jiangxi Qingfeng Pharma
Preclinical, Journal: Combination effect of azithromycin with TCM preparation Xiyanping injection against Klebsiella pneumoniae infection in rats. (Pubmed Central) - Aug 11, 2022
Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022333273, identifier PROSPERO 2022 CRD42022333273. The combination therapy of AZM and XYP showed increased antibacterial and anti-inflammatory properties, indicating that it might be used to treat K. pneumoniae infection.
- || oseltamivir / Generic mfg.
Retrospective data, Review: Traditional Chinese Medicine Injections Combined With Oseltamivir for Influenza: Systematic Review and Network Meta-Analysis. (Pubmed Central) - Aug 10, 2022
More high-quality studies examining the efficacy and safety of TCMIs are needed. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42021286994.
- |||||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Enrollment open: To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection (clinicaltrials.gov) - Aug 4, 2022
P3, N=552, Recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/, identifier CRD42021286994. Not yet recruiting --> Recruiting
- |||||||||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P3 trial: To Assess the Efficacy of GP681 Tablet Versus Placebo in Patients With Acute Uncomplicated Influenza Virus Infection (clinicaltrials.gov) - Jul 26, 2022
P3, N=552, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- |||| GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion, Trial primary completion date: A Clinical Study on the Safety and Efficacy of GP681 Tablets in the Treatment of Uncomplicated Acute Influenza (clinicaltrials.gov) - Jul 26, 2022
P2, N=216, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial primary completion date: Aug 2021 --> Dec 2021
- | Xiyanping / Jiangxi Qingfeng Pharma
Journal: The Pharmacological Mechanism of Xiyanping Injection for the Treatment of Novel Coronavirus Pneumonia (COVID-19): Based on Network Pharmacology Strategy. (Pubmed Central) - Jul 15, 2022
It acts on protein targets such as HSP90AA1 and plays a potential therapeutic role in COVID-19. Thus, compound III may be treated as a potential new drug for the treatment of COVID-19 and the Xiyanping injection may treat patients with COVID-19 infection.
- | Xiyanping / Jiangxi Qingfeng Pharma
Reimbursement, Journal: Concomitant Medication Use With Xiyanping Injection and the Risk of Suspected Allergic Reactions: A Nested Case-Control Study Based on China's National Medical Insurance Database. (Pubmed Central) - Jul 10, 2022
Increased risks for suspected allergic reactions were found for the concomitant use of XYP with seven medications. Our data suggest that gentamicin, cefoperazone-sulbactam, lidocaine, and ribavirin should be applied with precautions for patients receiving XYP, and further studies on drug interactions and allergy mechanisms are warranted.
- || Xiyanping / Jiangxi Qingfeng Pharma
Clinical, Retrospective data, Journal: Network Meta-analysis of heat-clearing and detoxifying Chinese medicine injections in treatment of acute exacerbation of chronic obstructive pulmonary disease (Pubmed Central) - Jun 22, 2022
According to the statistical difference and network Meta-analysis, the injections are in the order of(1)Reduning Injection+conventional western medicine>Tanreqing Injection+conventional western medicine in improving the effective rate,(2)Reduning Injection+conventional western medicine>Tanreqing Injection+conventional western medicine in decreasing C-reactive protein(CRP),(3)Reduning Injection+conventional western medicine>Xiyanping Injection+conventional western medicine>Tanreqing Injection+conventional western medicine in reducing white blood cell count(WBC),(4)Yuxingcao Injection+conventional western medicine>Reduning Injection+conventional western medicine>Tanreqing Injection+conventional western medicine in lowering partial pressure of carbon dioxide(PaCO_2),(5)Yuxingcao Injection+conventional western medicine>Reduning Injection+conventional western medicine>Tanreqing Injection+conventional western medicine>Xiyanping Injection+conventional western medicine in improving partial pressure of oxygen(PaO_2), and(6)Qingkailing Injection+conventional western medicine>Tanreqing Injection+conventional western medicine in shortening mean hospital stay...Among them, Reduning Injection+conventional western medicine and Tanreqing Injection+conventional western medicine demonstrate better and more effects. Due to the differences in the quantity and quality of included studies, the conclusion needs to be further verified.
- | Xiyanping / Jiangxi Qingfeng Pharma
Journal: Deciphering the potential anti-COVID-19 active ingredients in Andrographis paniculata (Burm. F.) Nees by combination of network pharmacology, molecular docking, and molecular dynamics. (Pubmed Central) - May 3, 2022
Ultimately, the application of molecular dynamics simulations demonstrated that andrographidine C could bind well to the ACE2 and PIK3CG proteins. This research identified novel molecules against COVID-19 for developing natural medicines from A. paniculate and also provides a possible explanation for the molecular mechanisms of Xiyanping Injection against COVID-19.
- || Xiyanping / Jiangxi Qingfeng Pharma
Retrospective data, Review: Comparative Efficacy of Chinese Herbal Injections for Septic Shock: A Bayesian Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Apr 26, 2022
Regarding procalcitonin level at 7-days, SF + WM, SM + WM, and Xiyanping injection (XYP)+WM were better than WM; XYP + WM was superior for SF + WM, SGM + WM, SM + WM, Danshen injection (DS)+WM, and XBJ + WM; XYP + WM ranked first...More and better evidence is needed to validate the conclusions. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/display_record.php?, identifier CRD42021282958.
- || Xiyanping / Jiangxi Qingfeng Pharma
Retrospective data, Review, Journal, HEOR: Comparative effectiveness of phlegm-heat clearing Chinese medicine injections for AECOPD: A systematic review and network meta-analysis. (Pubmed Central) - Apr 20, 2022
RDN and YXC are more effective in the alleviation of clinical symptoms. Given that the safety of YXC is controversial, TRQ and RDN may be preferable as phlegm-heat clearing CM injections in the adjuvant treatment of AECOPD.
- ||| Xiyanping / Jiangxi Qingfeng Pharma
Review, Journal, Adverse events: Clinical features of adverse events associated with Xiyanping-Ribavirin combination: A systematic review. (Pubmed Central) - Apr 20, 2022
Unless absolutely necessary, children should avoid combination therapy. More rigorous high-quality studies are needed to obtain more evidence.
- || Xiyanping / Jiangxi Qingfeng Pharma
Retrospective data, Review, Journal: Comparative Efficacy of Chinese Herbal Injections for Treating Severe Pneumonia: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Jan 28, 2022
Six CHIs including Xuebijing injection (XBJ), Tanreqing injection (TRQ), Reduning injection (RDN), Xiyanping injection (XYP), Shenfu injection (SF), and Shenmai injection (SM) were included...TRQ + WM showed an outstanding improvement in patients with SP considering both the clinical effective rate and other outcomes. Systematic Review Registration: [https://www.crd.york.ac.uk/prospero/], identifier [CRD42021244587].
- | Xiyanping / Jiangxi Qingfeng Pharma
Journal: Herb-Drug Interaction Between Xiyanping Injection and Lopinavir/Ritonavir, Two Agents Used in COVID-19 Pharmacotherapy. (Pubmed Central) - Dec 14, 2021
Our study demonstrated that XYPI affects the pharmacokinetics of LPV/RTV by inhibiting CYP3A4 activity. On the basis of this data, patients and clinicians can take precautions to avoid potential drug-interaction risks in COVID-19 treatment.
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
Trial completion, Trial completion date, Trial primary completion date: A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers (clinicaltrials.gov) - Dec 10, 2021
P1, N=6, Completed, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
On the basis of this data, patients and clinicians can take precautions to avoid potential drug-interaction risks in COVID-19 treatment. Not yet recruiting --> Completed | Trial completion date: Mar 2022 --> Nov 2021 | Trial primary completion date: Mar 2022 --> Nov 2021
- || GP681 / Jiangxi Qingfeng Pharma, GinkgoPharma
New P1 trial: A Phase I Mass Balance Study of [14C]GP681 in Healthy Chinese Male Volunteers (clinicaltrials.gov) - Nov 2, 2021
P1, N=6, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- ||| Xiyanping / Jiangxi Qingfeng Pharma
Clinical guideline, Retrospective data, Review, Journal: A Meta-Analysis of Treatment Effects on Viral Pneumonia Using TCM Injections Specified in the Clinical Guideline for COVID-19 in China. (Pubmed Central) - Oct 12, 2021
"COVID-19," "Viral pneumonia," "Tanreqing," "Xiyanping," "Reduning," "Xingnaojing," "Xuebijing," "Shenmai," "Shengmai," and "Shenfu" were used as keywords...However, clinical trials on TCM injections for the treatment of COVID-19 are still lacking. More high-quality clinical trials are still required.
- || Trial completion date, Trial initiation date, Trial primary completion date: QF-XYP2021-1: Efficacy and Safety of Intramuscular Injection of Xiyanping Injection in the Treatment of Acute Bronchitis in Children (clinicaltrials.gov) - Oct 3, 2021
P=N/A, N=80, Not yet recruiting, Sponsor: Jiangxi Qingfeng Pharmaceutical Co. Ltd.
More high-quality clinical trials are still required. Trial completion date: Jun 2022 --> Dec 2022 | Initiation date: Jul 2021 --> Oct 2021 | Trial primary completion date: Feb 2022 --> Sep 2022
- || Xiyanping / Jiangxi Qingfeng Pharma
Clinical, Review, Journal: Clinical Progress on Management of Pneumonia Due to COVID-19 With Chinese Traditional Patent Medicines. (Pubmed Central) - Sep 21, 2021
Findings from clinical studies and Chinese experience in using these CPMs showed that CPMs, when used in combination with conventional treatments, were effective in managing COVID-19 with few side effects. CPMs have excellent efficacy in managing COVID-19 with a great potential for clinical use.
- || Xiyanping / Jiangxi Qingfeng Pharma
Clinical, Journal: Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial. (Pubmed Central) - Sep 16, 2021
Taken together, XYP injection is safe and effective in improving the recovery of patients with mild to moderate COVID-19. However, further studies are warranted to evaluate the efficacy of XYP in an expanded cohort comprising COVID-19 patients at different disease stages.